Overview Request Sample Pages Request Customization Download PDF
You are viewing: Mexico Ophthalmology Drugs Market analysis
Part of: Ophthalmology Drugs Market (Global)

The Mexico Ophthalmology Drugs Market was valued at $0 Million in 2025 and projected to reach to $6.3 Million by 2030, representing a compound annual growth rate of CAGR 2.7%. Mexico's ophthalmology drugs market is positioned for steady, sustainable growth through 2030, with a CAGR of 2.7% reflecting the country's emerging status within Latin America's pharmaceutical sector.

Mexico Ophthalmology Drugs Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Mexico Ophthalmology Drugs Market Trends and Insights

  • In 2025, Mexico's market represents an emerging segment within Latin America's broader ophthalmology pharmaceutical landscape.
  • By 2030, Mexico is projected to reach USD 6.3 million, reflecting gradual expansion driven by increasing prevalence of eye disorders and improving healthcare access.
  • Mexico's market growth is more moderate compared to global trends, reflecting the country's unique healthcare infrastructure and demographic patterns.
  • The ophthalmology drugs sector in Mexico is characterized by rising demand for treatments addressing conditions such as dry eye syndrome, glaucoma, and age-related macular degeneration.
  • Mexico's pharmaceutical market continues to benefit from enhanced distribution networks and growing awareness of eye health among the population..

Key Market Statistics

  • CAGR (2025-2030) CAGR 2.7%
  • Market Size, 2025 ~USD 0 Million
  • Forecast, 2030 ~USD 6.3 Million
  • Country Mexico

Mexico Ophthalmology Drugs Market Overview

Steady Growth Trajectory :

Mexico's ophthalmology drugs market is projected to grow from USD 0 million in 2025 to USD 6.3 million by 2030, representing a CAGR of 2.7%, indicating consistent but measured expansion in the coming years.

Emerging Latin American Segment :

Mexico represents a developing opportunity within Latin America's ophthalmology pharmaceutical landscape, with growing recognition of eye health needs and increasing healthcare infrastructure investments across the country.

Rising Eye Disorder Prevalence :

Increasing prevalence of eye disorders including diabetic retinopathy, age-related macular degeneration, and dry eye syndrome is driving demand for specialized ophthalmology medications in Mexico's healthcare system.

Healthcare Access Improvements :

Enhanced healthcare accessibility and growing awareness of ophthalmological treatments among Mexican patients are contributing factors to the market's gradual expansion through 2030.

Mexico Ophthalmology Drugs Market Dynamics

  • The market expansion is underpinned by rising prevalence of chronic eye conditions, improved healthcare infrastructure, and increasing patient awareness of treatment options.
  • While growth rates remain moderate compared to global benchmarks (6.1% CAGR), Mexico presents a developing opportunity for pharmaceutical manufacturers seeking to establish or expand presence in the Latin American region. Key drivers include demographic shifts toward an aging population, higher incidence of diabetes-related eye complications, and gradual improvements in healthcare access across urban and semi-urban areas.
  • Pharmaceutical companies targeting Mexico should anticipate evolving regulatory frameworks and opportunities to introduce innovative treatments for prevalent eye conditions.
  • Strategic partnerships with local healthcare providers and investment in patient education initiatives will be critical for capturing market share in this emerging segment..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • Mexico's ophthalmology drugs market is projected to grow at a CAGR of 2.7% between 2025 and 2030, reaching USD 6.3 million by forecast year.
    • Mexico's market growth is driven by increasing prevalence of eye disorders and improved healthcare accessibility across the country.
    • Mexico represents an emerging but strategically important segment within the Latin American ophthalmology pharmaceutical market.
    • Mexico's market expansion is supported by strengthening distribution infrastructure and rising consumer awareness of eye health treatments.

    Ophthalmology Drugs Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment FARICIMAB (Molecule)
    Forecast Period 2025–2030
    Growth Rate CAGR of 6.1% from 2025 to 2030
    Largest Segment INTRAVITREAL (Route Of Administration)
    Market Size Base Year (Billions) ~USD 19.55 (2025)
    Revenue Forecast (Billions) ~USD 26.28 (2030)
    Segments Covered Molecule, Modality, Indication, Type, Route Of Administration, End User

    Mexico Ophthalmology Drugs Market Report Segmentation

    6 segment dimensions are covered across the global market.

    By Molecule

    • Aflibercept
    • Faricimab
    • Other Molecules
    • Ranibizumab

    By Modality

    • Monoclonal Antibodies & Fusion Proteins
    • Other Modalities
    • Small Molecules

    By Indication

    • Age-Related Macular Degeneration
    • Diabetic Macular Edema
    • Diabetic Retinopathy
    • Other Indications

    By Type

    • Dry Amd
    • Wet Amd

    By Route Of Administration

    • Intravitreal
    • Other Routes Of Administration
    • Topical

    By End User

    • Hospitals
    • Long-Term Care Facilities
    • Specialty Centers

    MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOSPITALS38.538.439.941.146.648.349.851.65.3
    LONG-TERM CARE FACILITIES7.87.788.29.39.69.910.24.9
    SPECIALTY CENTERS3.43.33.43.43.83.944.14
    TOTAL49.849.451.352.759.861.863.765.85.1

    Target Audience

    • Pharmaceutical Manufacturers : Pharmaceutical companies developing or marketing ophthalmology drugs need Mexico-specific market data to evaluate market potential, plan product launches, and establish distribution networks in this emerging segment.
    • Healthcare Investment Firms : Investment firms and private equity groups focused on healthcare require detailed market analysis of Mexico's ophthalmology sector to identify acquisition targets, assess growth potential, and make informed capital allocation decisions.
    • Market Research Professionals : Market analysts and research teams need comprehensive Mexico ophthalmology market data to support competitive intelligence, strategic planning, and client advisory services within the pharmaceutical and healthcare sectors.
    • Healthcare Policy Makers : Government agencies and healthcare policy officials in Mexico require market insights to develop evidence-based healthcare policies, allocate resources for eye health initiatives, and support pharmaceutical industry growth.
    • Medical Device and Distribution Companies : Distributors, medical device companies, and healthcare service providers need Mexico market intelligence to identify partnership opportunities, assess demand for ophthalmology solutions, and plan regional expansion strategies.

    Key Companies in the Mexico Ophthalmology Drugs Market

    CompanyHQOwnershipStrongest segments
    REGENERON PHARMACEUTICALS INC.United StatesPublic CompanyOphthalmology (EYLEA franchise),Immunology / Inflammation (Dupixent, Kevzara),Oncology / Hematology (Libtayo, bispecifics pipeline),
    BAYER AGGermanyPublic CompanyCrop Science (seeds, traits, crop protection, digital ag, services),Pharmaceuticals (cardiology, women’s health, oncology, hematology, ophthalmology, imaging, cell & gene),Consumer Health (OTC, self-care, supplements, dermatology, pain, digestive),
    NOVARTIS AGSwitzerlandPublic CompanyOncology and Hematology (Kisqali, Tafinlar+Mekinist, Pluvicto, Lutathera, Scemblix, Promacta/Revolade, Jakavi, Fabhalta),Cardiovascular, Renal and Metabolic (Entresto, Leqvio and related CVRM portfolio),Immunology and Neuroscience (Cosentyx, Xolair, Ilaris and related assets),
    ABBVIEUnited StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related),Oncology/Hematology (Imbruvica, Venclexta, Epkinly, Elahere, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev, migraine portfolio),
    APELLIS PHARMACEUTICALSUnited StatesPrivate CompanySYFOVRE – Geographic Atrophy,EMPAVELI – PNH and related indications,Pipeline and collaborations (APL-3007, APL-9099, Beam partnership),
    BIOGENUnited StatesPublic CompanyMultiple sclerosis franchise (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS-related),SMA and rare neurology (SPINRAZA, SKYCLARYS, QALSODY, zorevunersen pipeline linkage),Alzheimer’s and psychiatry (LEQEMBI, ZURZUVAE),
    BAUSCH + LOMBCanadaPublic CompanyVision Care (contact lenses, lens care, OTC eye care, vitamins),Pharmaceuticals (Rx and generic ophthalmics),Surgical (cataract, corneal, vitreous, retinal devices and IOLs),
    ASTELLAS PHARMA INC.JapanPublic CompanyOncology (XTANDI, XOSPATA, VYLOY, PADCEV),Urology (Betanis/Myrabetriq/BETMIGA),Immunology / Transplant (Prograf),
    FORMYCON AGGermanyPublic CompanyRanibizumab biosimilars (ophthalmology),Aflibercept biosimilars (ophthalmology),Ustekinumab biosimilar pipeline/early revenues,
    BIOCONIndiaPublic CompanyBiosimilars (oncology, diabetes, immunology),Generics and APIs,CRDMO (discovery, development, manufacturing services),
    SANDOZ GROUP AGSwitzerlandPublic CompanySmall-molecule generics (oral and injectable),Biosimilars,Specialty and rare disease off-patent medicines,
    SANTEN PHARMACEUTICAL CO., LTD.JapanPublic CompanyGlaucoma & ocular hypertension therapies,Dry eye & keratoconjunctival disease,Allergic conjunctivitis & inflammatory eye disease,
    INNOVENTChinaPublic CompanyOncology immunotherapy (PD-1, CTLA-4, combinations),Oncology targeted therapies and cell therapy,Autoimmune and ophthalmology biologics,
    OUTLOOK THERAPEUTICS, INC.United StatesPublic CompanyONS-5010 (ophthalmic bevacizumab for wet AMD and retinal diseases),Other pipeline / platform and collaboration-derived income,

    REGENERON PHARMACEUTICALS INC.

    Regeneron Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1988 with 15,343 employees. The company focuses on the discovery, development, and commercialization of medicines.

    BAYER AG

    Bayer AG is a German public company founded in 1863 with 87,757 employees, operating across pharmaceuticals, consumer health, and agricultural sciences. The company is one of the world's largest diversified life sciences organizations.

    NOVARTIS AG

    Novartis AG is a Swiss public pharmaceutical company founded in 1996 with 75,267 employees. The company develops and manufactures a broad range of innovative medicines and healthcare products.

    ABBVIE

    AbbVie is a United States-based public pharmaceutical company founded in 2012 with 57,000 employees. The company discovers, develops, and markets pharmaceutical products across multiple therapeutic areas.

    APELLIS PHARMACEUTICALS

    Apellis Pharmaceuticals is a United States-based private biopharmaceutical company founded in 2009 with 736 employees. The company focuses on the development of novel therapeutic candidates.

    BIOGEN

    Biogen is a United States-based public biotechnology company founded in 1978 with 7,500 employees. The company discovers, develops, manufactures, and delivers medicines primarily in neurology and immunology.

    BAUSCH + LOMB

    Bausch + Lomb is a Canadian public company founded in 1853 with 13,000 employees specializing in eye health and vision care products. The company is a global leader in the eye care industry.

    ASTELLAS PHARMA INC.

    Astellas Pharma Inc. is a Japanese public pharmaceutical company founded in 1923 with 14,099 employees. The company researches, develops, and commercializes pharmaceutical products worldwide.

    FORMYCON AG

    Formycon AG is a German public biopharmaceutical company founded in 1999 with 203 employees. The company specializes in the development of biosimilar medicines.

    BIOCON

    Biocon is an Indian public biopharmaceutical company founded in 1978 with 16,447 employees. The company develops and manufactures biopharmaceuticals, including biosimilars and small molecule drugs.

    SANDOZ GROUP AG

    Sandoz Group AG is a Swiss public pharmaceutical company founded in 1886 with 22,356 employees. The company is a global leader in generic and biosimilar medicines.

    SANTEN PHARMACEUTICAL CO., LTD.

    Santen Pharmaceutical Co., Ltd. is a Japanese public pharmaceutical company founded in 1890 with 3,968 employees. The company specializes in ophthalmic and other pharmaceutical products.

    INNOVENT

    Innovent is a Chinese public biopharmaceutical company founded in 2011 with 7,502 employees. The company focuses on the research and development of innovative biologics.

    OUTLOOK THERAPEUTICS, INC.

    Outlook Therapeutics, Inc. is a United States-based public biopharmaceutical company founded in 2010 with 17 employees. The company develops and commercializes ophthalmic therapeutic products.

    Reasons to Buy this Report

    • Market Entry Strategy Development : Gain comprehensive insights into Mexico's ophthalmology drug market dynamics to develop informed market entry strategies, identify growth opportunities, and assess competitive positioning within this emerging Latin American segment.
    • Forecast-Driven Investment Planning : Leverage accurate market projections (USD 6.3M by 2030, 2.7% CAGR) to guide investment decisions, resource allocation, and long-term business planning specific to Mexico's ophthalmology pharmaceutical sector.
    • Regulatory and Market Intelligence : Access detailed analysis of Mexico's healthcare regulatory environment, patient demographics, and disease prevalence patterns to inform product development, pricing strategies, and market positioning decisions.
    • Competitive Landscape Understanding : Understand key market drivers, emerging trends, and competitive dynamics specific to Mexico's ophthalmology market to identify white space opportunities and differentiation strategies for pharmaceutical products.
    • Regional Expansion Benchmarking : Compare Mexico's market performance against broader Latin American trends and global ophthalmology markets to benchmark growth potential and optimize regional expansion strategies across the Americas.

    Frequently asked questions

    What is the projected market size for ophthalmology drugs in Mexico by 2030?

    Mexico's ophthalmology drugs market is forecast to reach USD 6.3 million by 2030, growing from its 2025 baseline at a CAGR of 2.7%.

    What is the CAGR for Mexico's ophthalmology drugs market?

    Mexico's ophthalmology drugs market is expected to grow at a compound annual growth rate of 2.7% from 2025 to 2030.

    What are the primary drivers of growth in Mexico's ophthalmology drugs market?

    Mexico's market growth is primarily driven by increasing prevalence of eye disorders, improved healthcare access, enhanced distribution networks, and rising awareness of ophthalmology treatments among the population.

    How does Mexico's ophthalmology drugs market compare to global trends?

    Mexico's ophthalmology drugs market growth rate of 2.7% is more moderate than the global CAGR of 6.1%, reflecting Mexico's unique healthcare infrastructure and demographic characteristics.

    Which eye conditions are driving demand in Mexico's ophthalmology drugs market?

    Mexico's ophthalmology drugs market is experiencing rising demand for treatments addressing dry eye syndrome, glaucoma, age-related macular degeneration, and other prevalent eye disorders.

    RESEARCH METHODOLOGY

    This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global ophthalmology drugs market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the ophthalmology drugs market. The secondary sources used for this study include US Food and Drug Administration (US FDA), European Medicines Agency (EMA), World Health Organization (WHO), National Center for Biotechnology Information (NCBI), White papers, Company Websites, Interviews with Experts, Annual Reports, SEC Filings, Investor Presentations, and MarketsandMarkets Analysis. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    A comprehensive primary research was undertaken following an initial assessment of the global ophthalmology drugs market landscape through secondary research. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from hospitals, long-term care facilities, and specialty centers. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.

    The following is a breakdown of the primary respondents:

    Ophthalmology Drugs Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both bottom-up and top-down approaches were used to estimate and validate the total size of the ophthalmology drugs market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • A list of the major global players operating in the ophthalmology drugs market was generated.
    • The revenues generated from their ophthalmology drug products have been determined through annual reports and secondary sources (including paid databases).
    • The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Ophthalmology Drugs Market Size: Bottom-up and Top-down Approaches

    Ophthalmology Drugs Market

    Data Triangulation

    After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Ophthalmology drugs are specifically designed to treat or prevent eye diseases and disorders. These medications target various parts of the eye, including the cornea, conjunctiva, lens, retina, and optic nerve. The market includes a range of effective therapies across different drug modalities, such as biologics and biosimilars (e.g., anti-VEGF drugs, monoclonal antibodies, oligonucleotides, and peptides), small molecules, gene therapy, and cell therapy. These treatments address various conditions, including age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, retinal vein occlusion, uveitis, and neurotrophic keratitis, among others.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Patient advocacy organizations
    • Specialty clinics
    • Long-term care facilities
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists    

    Report Objectives

    • To define, describe, and forecast the ophthalmology drugs market by molecule, modality, route of administration, indication, end user, and region
    • To provide detailed information regarding the factors influencing market growth (such as drivers, opportunities, restraints, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall ophthalmology drugs market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To profile the key players in the global ophthalmology drugs market as well as comprehensively analyze their core competencies and market rankings
    • To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To track and analyze competitive developments, such as product launches & approvals, expansions, acquisitions, partnerships, product pipelines, collaborations, and agreements, in the ophthalmology drugs market

     

    Get the Full Ophthalmology Drugs Market Report

    Full forecast, segment splits, and company analysis for all Ophthalmology Drugs Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status